AURORA, ON, June 10, 2013 /CNW/ - After another successful year,
Prollenium Medical Technologies Inc. has been ranked no. 292 on the
PROFIT 500 list of Canada's top 500 fastest-growing companies. The list
was published in the Summer 2013 issue of PROFIT and on PROFITguide.com. Companies on the list are ranked nationally, regionally/city, and by
industry. Prollenium is based outside of Toronto (in the GTA) and is
categorized within the Business Products (manufacturing and
PROFIT 500 ranks Canada's fastest-growing companies based on five-year
revenue growth. This year, a 190% growth in revenue from 2007-2012 puts
Prollenium- a manufacturer of cutting edge products in tissue
reconstruction- on the list yet again. This is Prollenium's 5th consecutive year of recognition. Since its founding in 2002, the
company has continued to see success with its extensive offering of
innovative products and penetration into new markets globally.
"Without the hard work and dedication of the group here at Prollenium,
the company would not be where it is today," says Chief Executive, Ario
Khoshbin. "I am very proud of the team we have built here." In the past
five years, Prollenium has increased its workforce by more than 5 times
its count in 2007. With Canada's only facility for the manufacturing of
dermal fillers, the company has dedicated its attention to areas of
urology, dermatology, osteoarthritis and podiatry.
"It is a great accomplishment to make the list once again. We have very
high expectations and are extremely optimistic about our future in the
marketplace. With our pipeline of products and market intelligence we
remain focused on developing strong partnerships offering safe and
efficacious products worldwide," says Khasha Ighanian, Senior Vice
President. Prollenium exports to over 80 countries globally and
continues to focus heavily in R&D. The company plans to launch several
new products in the near future.
For more information, please visit www.prollenium.com
Prollenium Medical Technologies Inc. is a Canadian-based company,
founded in 2002, dedicated to the research, design, manufacture and
distribution of implantable polymers in the
pharmaceutical/dermatological industry. The company is committed to
providing innovative products worldwide that are safe and viable.
Flagship product lines include Revanesse®, Phiderma® and RheoVital™.
SOURCE: Prollenium Medical Technologies Inc.
For further information: